Acute extrapyramidal syndrome in mild ornithine transcarbamylase deficiency: metabolic stroke involving the caudate and putamen without metabolic decompensation by Keegan, Catherine E. et al.
ORIGINAL PAPER
Acute extrapyramidal syndrome in mild ornithine transcarbamylase
deficiency: metabolic stroke involving the caudate and putamen
without metabolic decompensation
Received: 26 July 2002 / Revised: 28 October 2002 / Accepted: 5 November 2002 / Published online: 7 February 2003
 Springer-Verlag 2003
Abstract A 6-year-old male with partial ornithine
transcarbamylase (OTC) deficiency had acute and
rapidly progressive symmetrical swelling of the head of
the caudate nuclei and putamina. Clinical presentation
was ataxia and dysarthria progressing to seizures and
coma; these symptoms gradually resolved with sup-
portive management. Although he had been recently
treated for mild hyperammonemia, there was no evi-
dence of acute metabolic decompensation prior to
presentation, and plasma ammonia and amino acids
were consistent with good metabolic control. This case
is novel in that the neurological insult affected the
neostriatum of the basal ganglia and the episode
occurred in the absence of an apparent metabolic ab-
normality, unique observations in a patient with OTC
deficiency. Conclusion: This case suggests that the
pathophysiology of metabolic stroke is complicated. It
also argues for an evaluation for metabolic stroke in
patients with known inborn errors of metabolism who
present with unusual neurological symptoms in the
absence of biochemical abnormalities. Similarly, this
case suggests that patients presenting with unexplained
neurological insults might benefit from an evaluation
for an inborn error of metabolism.
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Ornithine transcarbamylase (OTC) deficiency (MIM
311250) is the most common urea cycle disorder, with an
estimated incidence of 1/14,000 [2]. Urea cycle disorders
usually present in the neonatal period with encephal-
opathy and hyperammonemia (typically greater than
200 lM; normal 11–35 lM) without increased anion
gap. Older patients with hyperammonemia due to met-
abolic decompensation commonly present with ataxia,
dysarthria and/or mental status changes. Hyperam-
monemia is a medical emergency; untreated it leads to
astrocyte swelling and generalized cerebral edema [2].
Unless treatment is rapidly instituted, developmental
delay and mental retardation are likely; neurological
outcome is correlated with the frequency and duration
of hyperammonemic encephalopathy [17, 18, 23].
Metabolic stroke, defined as acute focal neurological
deficits with correlated lesions on brain imaging, is a
well-documented but poorly understood complication of
certain inborn errors of metabolism. In previously re-
ported patients, these episodes were typically accompa-
nied by acute metabolic decompensation with significant
biochemical abnormalities [4, 5, 11, 12, 13, 15, 20, 22].
Some cases were reversible [4, 12, 20, 22], while other
cases were fatal [5, 8, 9, 10, 13]. Here we describe a
patient with OTC deficiency who, despite evidence of
good metabolic control at the onset of symptoms, de-
veloped a reversible neurological insult to the neostria-
tum (caudate and putamen). This case is novel; to our
knowledge, acute reversible insults to the neostriatum
have not been reported in patients with OTC deficiency.
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This observation suggests that factors other than acute
systemic metabolic decompensation may account for
this stroke-like syndrome.
Case History
D.A. was born to a 31-year-old woman who had a confirmed
family history of OTC deficiency (Fig. 1). Biochemical abnormal-
ities consistent with the diagnosis of OTC deficiency, including
hyperammonemia, elevated plasma glutamine and urinary orotic
acid with low plasma arginine and citrulline were noted in infancy.
Previous mutational analyses of the OTC gene in a maternal cousin
showed a Y202H missense mutation (CAC>TAC) (Fig. 1); this
mutation was reported in an unrelated individual with OTC defi-
ciency who presented at 2 years of age with hyperammonemia and
encephalopathy [1]. Diagnostic biochemical abnormalities, a family
history of OTC deficiency, and DNA diagnostic studies in an af-
fected maternal cousin confirmed the diagnosis of OTC deficiency
in our patient.
D.A. had numerous hospitalizations for hyperammonemia
presenting as lethargy and transient ataxia; these had been suc-
cessfully treated with protein restriction and intravenous sodium
benzoate and sodium phenylacetate. Laboratory values from a
typical hospitalization at age 5.5 years are shown in Table 1. D.A.
had delayed developmental milestones; at age 4, he was ambulatory
and had minimal expressive language. By age 5, he used utensils
and was toilet trained. He was diagnosed with attention deficit
hyperactivity disorder and had significant behavioral problems
including property destruction and the mistreatment of animals.
At age 5 and 11/12 years, he presented with a broad based gait,
hyperammonemia (131 lM), and a presumed viral infection. He
was treated with intravenous sodium benzoate, sodium phenylac-
etate, and arginine and was discharged after a 3-day hospitalization
with a normal neurological examination and a normal ammonia
level. Twenty-four hours after discharge, he presented with acute
onset of ataxia, drooling, and slurred speech without associated
symptoms. His ammonia was 22 lM (normal, 11–35). Plasma
glutamine was moderately elevated at 721 lM (normal, 123–600);
citrulline and arginine were within normal limits. Essential amino
acids, albumin, and total protein were normal, reflecting adequate
nutritional status and liver protein synthesis (Table 1). A
non-contrast head CT scan was normal, with no evidence of
acute hemorrhage, ischemia, or infarction. He remained stable
metabolically, but worsening ataxia and dysarthria prompted a
brain MRI on hospital day 2, which showed mild increased signal
intensity in the putamina and head of the caudate nuclei, consistent
with gray matter swelling (Fig. 2A). On hospital day 3, he devel-
oped right-sided seizures and coma. He had brisk deep tendon
reflexes, ankle clonus and a left Babinski sign; intermittent chore-
iform movements of the arms were noted. Repeat non-contrast
head CT scans on hospital days 3 and 4 showed subtle interval
development of decreased attenuation in the basal ganglia, con-
sistent with focal edema (Fig. 2B). There was no evidence of diffuse
cerebral edema, acute hemorrhage or ischemia. A prothrombin
time was slightly elevated; serum albumin and total protein
remained normal, indicating normal liver function (Table 1).
Just prior to the onset of seizures, D.A.’s ammonia level was
98 lM (Table 1). He was treated with intravenous sodium benzo-
ate, sodium phenylacetate and arginine, and his ammonia level
quickly normalized. During his acute ataxia and seizures, his
plasma glutamine was normal (267 lM) and he had a normal urine
organic acid profile. Serial arterial lactate and pyruvate measure-
ments during his hospitalization were normal. CSF for lactate and
quantitative amino acids were also normal (Table 1). Additionally,
mitochondrial DNA mutational analyses for tRNA leucine muta-
tions associated with MELAS (mitochondrial myopathyencephal-
opathy-lactic acidosis and stroke-like episodes; MIM 540000) were
normal. Lumbar puncture showed normal white and red blood cell
counts, protein, glucose, Gram stain and culture. Blood and CSF
viral cultures, and CSF PCR for herpes simplex virus were nega-
tive. A blood lead level, carboxyhemoglobin determination, and
hair analysis for heavy metals were normal; an HIV antibody test
was also negative.
An EEG on hospital day 4 showed diffuse suppression, con-
sistent with moderate encephalopathy. Repeat brain MRI on
hospital day 9 showed increased signal intensity in the head of the
caudate nuclei and putamina, consistent with progression of the
edema in these regions (Fig. 2C and D). His neurological status
gradually improved with supportive care, and he was extubated on
hospital day 15. At discharge on hospital day 33, he was eating
normally, speaking with some dysarthria, walking with assistance,
and riding a tricycle. After 3 additional weeks, he had returned to
his baseline behavioral and neurological status; he was walking,
running, and speaking in full sentences. He continued to have mild
difficulties with balance and a resting hand tremor.
Discussion
We present a 6-year-old male with partial OTC defi-
ciency who acutely developed edema of the neostriatum
with correlative symptoms in the setting of normal
biochemical parameters. The presenting symptoms of
ataxia and dysarthria were more severe than those pre-
viously observed during previous episodes of hyperam-
monemia. His ammonia at the time of presentation was
Fig. 1 Four-generation pedigree showing males (h), females (s),
and obligate carrier females (). P indicates the propositus, D.A.
(IV-11). Individuals III-8, -10, and -23 and IV-6, -8, -10, and -11
had biochemical evidence of OTC; individual IV-13 had a Y202H
missense OTC mutation. Males who died in infancy (individuals II-
3, III-3, -4, -15, -16, and IV-5) are presumed to have had OTC
deficiency. Spontaneous abortions are indicated (’). Ages are given
for deceased individuals (III-12) or infants (inf )
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in the normal range and his glutamine was only mod-
estly elevated. Essential amino acids, total protein and
serum albumin concentrations were normal, reflecting
adequate nutritional status. Although he had recently
been hospitalized with mild hyperammonia, he had
returned to his baseline status 24 h prior to the onset of
his new acute symptoms. Head MRI scans showed evi-
dence of injury to the basal ganglia, specifically in the
head of the caudate nuclei and the putamina. Ulti-
mately, his neurological status improved and he was left
with minimal residual neurological deficits. To our
knowledge, metabolic stroke affecting the basal ganglia
without associated metabolic derangement in a patient
with OTC deficiency has not been described previously.
Metabolic stroke has been described in patients with
urea cycle defects, including several patients with OTC
deficiency and in one patient with carbamyl phosphate
synthetase (CPS) deficiency (MIM 237300) [4, 5, 13, 15,
20]. Each of these patients presented with hemiparesis
and hyperammonemia in the range of 300–400 lM, and
all had a CT or MRI pattern consistent with infarction
Fig. 2A–D Results of neuroimaging studies. A Axial fluid attenu-
ated inversion recovery (FLAIR) MR scan on hospital day 2
demonstrates mild increased signal from the putamina (long
arrows) and more subtle increased signal from the head of the
caudate nuclei (short arrows) bilaterally. The globi pallidi (arrow
heads) display normal signal. B Non-contrast axial CT scan on
hospital day 4 demonstrates subtle decreased attenuation from
region of the putamina (long arrows). C Axial fluid attenuated
inversion recovery (FLAIR) MR scan on hospital day 9 demon-
strates progressive increase in signal from the putamina (long
arrows) and head of the caudate nuclei (short arrows) over 7 days.
D Contrast-enhanced T1-weighted MR scan shows mild local mass
effect associated with the putaminal abnormalities, no enhance-
ment is seen (long arrows). The globi pallidi (arrow heads) are
normal on both FLAIR and T1-weighted images















NH3a 264 131 22 98 12 17 11–35
Glutaminea 1207 910d 721 267 471 499 123–600
Alaninea 185 1210d 843 510 682 303 141–343
Citrullinea 1 76d 26 6 22 13 2–41
Argininea 42 74d 78 112 136 47 40–145
Threoninea 45 110d 95 42 66 157 85–196
Valinea 99 116d 177 55 47 130 112–284
Cystinea 33 25d 30 39 40 18 3–48
Isoleucinea 34 25d 37 12 10 43 35–79
Leucinea 59 40d 79 22 18 72 60–168
Phenylalaninea 33 48d 42 37 24 31 30–70
Tryptophana 24 0d 18 17 22 20 0–123
Lysinea 207 164d 141 75 92 102 81–213
Histidinea 77 94d 61 65 45 54 47–104
Lactateb – – – 0.6 – – 0.5–2.2
Pyruvateb – – – 0.05 – – 0.03–0.15
CSF glutaminea – – – 454 – – 161–533
CSF lactateb – – – 2.2 – – 0.5–2.2
Albuminc 4.8 4.5 3.9 3.4 3.2 – 3.2–5.2
Total proteinc 7.7 7.2 6.5 6.1 – – 5.8–8
Prothrombinetime/INR – – – 11.8/1.2 – – 9.3–11.1
aPlasma or CSF concentrations; all values in micromolar (lM)
bSerum or CSF concentrations in milliequivalents/liter
cSerum concentrations in grams/deciliter
dValues obtained 2 weeks prior to presentation
eValues are in seconds. Dashes (–) denote values not obtainedf
b
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or ischemia of the cerebral cortex. None of these patients
had evidence of damage to the basal ganglia as seen in
our patient. Interestingly, the four patients with OTC
deficiency were heterozygous females, and the diagnosis
of OTC deficiency was made after the onset of stroke-
like symptoms [4, 5, 13, 15].
Stroke-like symptoms are relatively uncommon in
patients with inborn errors of metabolism. Excluding
mitochondrial disorders, such as Leigh syndrome (MIM
256000) and MELAS (MIM 540000), metabolic stroke
has been reported in approximately 20 patients. There
appears to be some specificity for certain affected regions
of the brain, depending on the type of metabolic disor-
der (Table 2). Patients with organic acidemias, including
methylmalonic acidemia (MIM 251000) and propionic
acidemia (MIM 606054), have been described with acute
injuries to the basal ganglia; however, of note, these
patients had injuries to the globus pallidus, not the
neostriatum [8, 11, 12, 22]. In addition, all but one of
these patients had metabolic decompensation with sig-
nificant acidosis at the time of presentation [8]. The re-
cent observation of a patient with methylmalonic
acidemia who suffered a metabolic stroke while in good
metabolic control almost 5 years after liver transplan-
tation suggests that factors other than hepatic correction
of enzyme activity may predispose to metabolic stroke
[3].
A number of mechanisms have been proposed to
account for the neurological abnormalities associated
with metabolic stroke. These include the accumulation
of toxic substances within the basal ganglia [22], hyp-
oxic-ischemic (watershed) injury [13, 15], severe ketoac-
idosis [11], and accumulation of glutamine in the brain
[20]. The basal ganglia are thought to be especially
susceptible to hypoxic and/or ischemic damage, and
necrosis of the globus pallidus is a frequent acute com-
plication of exposure to both carbon monoxide and
cyanide [11], both of which were ruled out in our patient.
Given this increased requirement for oxidative metabo-
lism, it has been hypothesized that basal ganglia injuries
in patients with metabolic stroke are due to a deficiency
of mitochondrial energy metabolism [9]; however, the
exact mechanism of injury to the brain is unknown.
In summary, metabolic stroke is a recognized com-
plication of several different inborn errors of metabo-
lism. The etiology of this neurological insult is unknown,
but possibly involves accumulation of toxic intermedi-
ates or disruption of mitochondrial function. To our
knowledge, this is the first report of metabolic stroke in
OTC deficiency involving the basal ganglia and occur-
ring in the absence of acute metabolic decompensation.
Our report suggests that patients with inborn errors
presenting with neurological symptoms and normal
biochemical parameters should be evaluated carefully
for the development of metabolic stroke. Similarly, pa-
tients with acute, unexplained neurological insults
should be evaluated for inborn errors of metabolism.
This case adds to the expanding list of disorders with a
variety of presentations that can be classified as meta-
bolic stroke.
References
1. Anadiotis G, Ierardi-Curto L, Kaplan PB, Berry GT (2001)
Ornithine transcarbamylase deficiency and pancreatitis. J Pe-
diatr 138: 123–124
2. Brusilow SW, Maestri NE (1996) Urea cycle disorders: diag-
nosis, pathophysiology, and therapy. Adv Pediatr 43: 127–170
3. Chakrapani A, Sivakumar P, McKiernan PJ, Leonard JV
(2002) Metabolic stroke in methylmalonic acidemia five years
after liver transplantation. J Pediatr 140: 261–263
4. Christodoulou J, Qureshi IA, McInnes RR, Clarke JT (1993)
Ornithine transcarbamylase deficiency presenting with stroke-
like episodes. J Pediatr 122: 423–425
5. De Grauw TJ, Smit LM, Brockstedt M, Meijer Y, vd Klei-von
Moorsel J, Jakobs C (1990) Acute hemiparesis as the presenting
sign in a heterozygote for ornithine transcarbamylase defi-
ciency. Neuropediatrics 21: 133–135
6. Fischer AQ, Challa VR, Burton BK, McLean WT (1981)
Cerebellar hemorrhage complicating isovaleric acidemia: a case
report. Neurology 31: 746–748
7. Goodman SI, Norenberg MD, Shikes RH, Breslich DJ, Moe
PG (1977). Glutaric aciduria: biochemical and morphologic
considerations. J Pediatr 90: 746–750
8. Haas RH, Marsden DL, Capistrano-Estrada S, Hamilton R,
Grafe MR, Wong W, Nyhan WL (1995) Acute basal ganglia
infarction in propionic acidemia. J Child Neurol 10: 18–22
9. Hamilton RL, Haas RH, Nyhan WL, Powell HC, Grafe MR
(1995) Neuropathology of propionic acidemia: a report of
Table 2 CNS regions affected in metabolic stroke





Current patient – – – +
OTC + – – – [4, 5,13, 15]
CPS + – – – [20]
Propionicacidemia – + + – [8, 9,10]
Methylmalonicacidemia – + + – [3, 11,12, 22]
Glutaricacidemia type I – – – + [7, 14]
Isovalericacidemia – + – – [6]
3-methylcrotonyl CoA carboxylase + – – – [21]
Leighsyndrome + + + + [16, 19]
MELAS + + + + [19]
OTC ornithine transcarbamylase deficiency; CPS carbamyl phosphate synthetase deficiency; MELAS mitochondrial myopathy enceph-
alopathy lactic acidosis stroke-like episodes
262
two patients with basal ganglia lesions. J Child Neurol 10: 25–
30
10. Harding BN, Leonard JV, Erdohazi M (1991) Propionic
acidaemia: a neuropathological study of two patients present-
ing in infancy. Neuropathol Appl Neurobiol 17: 133–138
11. Heidenreich R, Natowicz M, Hainline BE, Berman P, Kelley
RI, Hillman RE, Berry GT (1988) Acute extrapyramidal syn-
drome in methylmalonic acidemia: ‘‘metabolic stroke’’ involv-
ing the globus pallidus. J Pediatr 113: 1022–1027
12. Korf B, Wallman JK, Levy HL (1986) Bilateral lucency of the
globus pallidus complicating methylmalonic acidemia. Ann
Neurol 20: 364–366
13. Lacey DJ, Duffner PK, Cohen ME, Mosovich L (1986) Un-
usual biochemical and clinical features in a girl with ornithine
transcarbamylase deficiency. Pediatr Neurol 2: 51–53
14. Leibel RL, Shih VE, Goodman SI, Bauman ML, McCabe ER,
Zwerdling RG, Bergman I, Costello C (1980) Glutaric acide-
mia: a metabolic disorder causing progressive choreoathetosis.
Neurology 30: 1163–1168
15. Mamourian AC, du Plessis A (1991) Urea cycle defect: a case
with MR and CT findings resembling infarct. Pediatr Radiol
21: 594–595
16. Medina L, Chi TL, DeVivo DC, Hilal SK (1990) MR findings
in patients with subacute necrotizing encephalomyelopathy
(Leigh syndrome): correlation with biochemical defect. AJR
Am J Roentgenol 154: 1269–1274
17. Msall M, Batshaw ML, Suss R, Brusilow SW, Mellits ED
(1984) Neurologic outcome in children with inborn errors of
urea synthesis. Outcome of urea-cycle enzymopathies. N Engl
J Med 310: 1500–1505
18. Picca S, Dionisi-Vici C, Abeni D, Pastore A, Rizzo C, Orzalesi
M, Sabetta G, Rizzoni G, Bartuli A (2001) Extracorporeal
dialysis in neonatal hyperammonemia: modalities and prog-
nostic indicators. Pediatr Nephrol 16: 862–867
19. Shoffner JM (2001) Oxidative phosphorylation diseases. In:
Scriver CM, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler
KW, Vogelstein B (eds) The metabolic and molecular bases of
inherited disease. McGraw-Hill, New York, pp 2367–2423
20. Sperl W, Felber S, Skladal D, Wermuth B (1997) Metabolic
stroke in carbamyl phosphate synthetase deficiency. Neurope-
diatrics 28: 229–234
21. Steen C, Baumgartner ER, Duran M, Lehnert W, Suormala T,
Fingerhut SR, Stehn M, Kohlschutter A (1999). Metabolic
stroke in isolated 3-methylcrotonyl-CoA carboxylase deficien-
cy. Eur J Pediatr 158: 730–733
22. Thompson GN, Christodoulou J, Danks DM (1989) Metabolic
stroke in methylmalonic acidemia. J Pediatr 115: 499–500
23. Uchino T, Endo F, Matsuda I (1998). Neurodevelopmental
outcome of long-term therapy of urea cycle disorders in Japan.
J Inherit Metab Dis 21(Suppl 1): 151–159
263
